Lower antiretroviral dose still suppresses HIV
Results of the double-blind placebo controlled ENCORE1 study were presented at the International AIDS Society Conference in Kuala Lumpur, Malaysia this week.
“A reduced daily dose should translate into a lower cost of treatment and permit more effective and efficient use of healthcare resources,” said UNSW Professor Sean Emery, protocol chairperson of the study and head of the Therapeutic and Vaccine Research Program at the Kirby Institute.
“Essentially, more people could receive this life-saving treatment for the same amount of funding.”
A total of 630 HIV-positive participants from 13 countries in Africa, Asia, Australia, Europe and Latin America took part in the trial. Half took two-thirds of the current standard daily dose while the control group took the full standard dose. Participants were observed regularly for a year. The results indicate that reducing the daily dose by one-third, from 600mg down to 400mg,